Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03919955 · ClinicalTrials.gov registry record · Phase 2
A Novel Pharmacological Therapy for Obstructive Sleep Apnea
A Phase 2 study, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 117
- Enrollment target
NCT03919955 is a Phase 2 study that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 117 participants.
The verdict
NCT03919955, a Phase 2 study, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 117 participants
- Enrollment target
Study Summary
A pharmacological, non-mechanical therapy for OSA that is efficacious and tolerable remains elusive. Here the investigators study the effect on sleep apnea severity of a combination of pharmacological agents (atomoxetine and oxybutynin, "AtoOxy") over a 1 month period of time. The current study will answer the following questions: Does ongoing, repeated-dose administration of atomoxetine-plus-oxybutynin (referred to as "AtoOxy") improve OSA severity, and do patients exhibit signs of symptomatic relief? Most importantly, which phenotypic subgroup of patients preferentially benefit from this intervention?
Interventions
- DRUG Placebo
- DRUG Atomoxetine
- DRUG Oxybutynin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 117 participants |
| Start Date | 2019-09-03 |
| Est. Completion | 2023-09-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03919955
The ClinicalTrials.gov registry entry for NCT03919955 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 117 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03919955 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03919955 about?
NCT03919955 is a clinical study titled "A Novel Pharmacological Therapy for Obstructive Sleep Apnea". A pharmacological, non-mechanical therapy for OSA that is efficacious and tolerable remains elusive. Here the investigators study the effect on sleep apnea severity of a combination of pharmacological agents (atomoxetine and oxybutynin, "AtoOxy") over a 1 month period of time. The current study will...
What is the current status of trial NCT03919955?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 117 participants. The study started on 2019-09-03. Estimated completion is 2023-09-07.
What interventions are being tested in trial NCT03919955?
The interventions under investigation include: Placebo (DRUG), Atomoxetine (DRUG), Oxybutynin (DRUG).
Who is sponsoring clinical trial NCT03919955?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.